Product logins

Find logins to all Clarivate products below.


Key trends to watch:
Rethinking the research paradigm for women’s health

Discover more about key trends in women’s health.

Addressing decades of under-representation

Historical under-representation in research and funding has left many women’s health conditions, including female-specific conditions and diseases affecting women differently than men, underdiagnosed and undertreated.

Growing awareness, stronger equity frameworks and regulatory focus are driving new opportunities for pharma to close these gaps. Next-generation therapies promise more precise, personalized approaches that address unmet needs across cancers, chronic conditions and beyond.

Closing disparities in women’s health research

The disparities in funding for women’s health research have resulted in poorer outcomes for some highly lethal diseases. Targeted funding and innovation are key to advancing women’s health and delivering meaningful progress.

16% to 57%
five-year net survival rates have been documented for ovarian cancer globally.

(Allemani et al, 2018)
2.1%
of global public and philanthropic funding is granted to ovarian cancer research.

(McIntosh et al, 2023)
11.2%
of global public and philanthropic funding is granted to breast cancer research.

(McIntosh et al, 2023)

Emerging drugs in women’s health

The Drugs to Watch in this category exemplify the opportunities pharma is taking to step in and help address long-standing unmet health needs for the female population worldwide.

Gedatolisib
Breast cancer
INLEXZO™ (TAR-200)
Bladder cancer
Relacorilant
Ovarian cancer and hypercortisolism (Cushing syndrome)